3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
45
Gynecologic
2
Thoracic
1
Head & Neck
1
Genitourinary
1
Breast
1
Conditions
Head and Neck Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
8
Nasopharyngeal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Salivary Gland Neoplasms
2
Recurrence
2
Osteosarcoma
2
Optic Nerve Glioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasm Metastasis
2
Melanoma
2
Familial ependymoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Astrocytoma
2
Wilms Tumor
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Teratoma
1
Spinocerebellar Degenerations
1
Interventions
pembrolizumab
9
Nivolumab
4
Magnetic Resonance Spectroscopy
3
spartalizumab
2
Ipilimumab
2
Gemcitabine
2
Fluorodeoxyglucose F18
2
FAPI-46
2
Drug Therapy
2
Cisplatin
2
zenocutuzumab
1
venetoclax
1
ulixertinib
1
trametinib
1
tislelizumab
1
seribantumab
1
rovalpituzumab tesirine
1
pazopanib
1
neratinib
1
margetuximab
1
lenvatinib
1
entrectinib
1
durvalumab
1
cobimetinib
1
cemiplimab
1
budigalimab
1
bemarituzumab
1
atezolizumab
1
alectinib
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
Oxaliplatin
×
Head & Neck
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled